gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Cancer/testis antigen 1B

The protein encoded by this gene is an antigen that is overexpressed in many cancers but that is also expressed in normal testis. This gene is found in a duplicated region of the X-chromosome and therefore has a neighboring gene of identical sequence. [provided by RefSeq, Jan 2012] (from NCBI)
Top mentioned proteins: CAN, CD8, HAD, CD4, MHC
Papers on NY-ESO-1
Optimization of Norovirus Virus-Like Particle Production in Pichia Pastoris Using a Real-Time Near-Infrared Bioprocess Monitor.
Batt et al., Ithaca, United States. In Biotechnol Prog, Feb 2016
UNASSIGNED: The production of norovirus virus-like particles (NoV VLPs) displaying NY-ESO-1 cancer testis antigen in Pichia pastoris BG11 Mut(S) has been enhanced through feed-strategy optimization using a near-infrared bioprocess monitor (RTBio® Bioprocess Monitor, ASL Analytical, Inc.), capable of monitoring and controlling the concentrations of glycerol and methanol in real-time.
The Tumor Antigen NY-ESO-1 Mediates Direct Recognition of Melanoma Cells by CD4+ T Cells after Intercellular Antigen Transfer.
Gannagé et al., Nantes, France. In J Immunol, Feb 2016
NY-ESO-1-specific CD4(+) T cells are of interest for immune therapy against tumors, because it has been shown that their transfer into a patient with melanoma resulted in tumor regression.
Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic Cancers.
Rosenberg et al., Bethesda, United States. In J Immunother, Jan 2016
Melanoma-associated antigen-A (MAGE-A) and New York esophageal squamous cell cancer-1 (NY-ESO-1) are 2 cancer testis antigens (CTA) demonstrating potential for use in targeted immunotherapy.
CD4(+) T helper cell responses to NY-ESO-1 tumor antigen in ovarian cancer resist perversion into immunosuppressive Tregs.
Ayyoub et al., Saint-Herblain, France. In Oncoimmunology, Dec 2015
UNASSIGNED: In a recent study, we have demonstrated that T helper type 1 (TH1) cells specific for the tumor antigen NY-ESO-1 are amplified at ovarian tumor sites but are not "perverted" into immunosuppressive FOXP3(+) regulatory T cells (Tregs).
Immunotherapy in Sarcoma: Future Horizons.
Tawbi et al., Pittsburgh, United States. In Curr Oncol Rep, Nov 2015
A promising strategy includes adoptive T cell therapy which has been studied in small cohorts of synovial sarcoma, a subtype that is known to widely express the cancer testis antigen, NY-ESO-1.
Immunotherapy in Multiple Myeloma Using Cancer-Testis Antigens.
Esfandiary et al., Tehrān, Iran. In Iran J Cancer Prev, Oct 2015
RESULTS: Several CTAs including NY-ESO-1, MAGE and GAGE family have been shown to be expressed in MM patients.
Engineering Anti-myeloma Responses Using Affinity-Enhanced TCR-Engineered T Cells.
Lasarte et al., Pamplona, Spain. In Cancer Cell, Oct 2015
NY-ESO-1 TCR-engineered T cells have shown activity in solid tumors.
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.
June et al., Baltimore, United States. In Nat Med, Aug 2015
Here we report results of a phase I/II trial to evaluate the safety and activity of autologous T cells engineered to express an affinity-enhanced T cell receptor (TCR) recognizing a naturally processed peptide shared by the cancer-testis antigens NY-ESO-1 and LAGE-1.
Immunotherapeutic approaches to sarcoma.
Tawbi et al., Pittsburgh, United States. In Curr Treat Options Oncol, Jun 2015
More promising results have been reported in small studies evaluating vaccines and adoptive T cell therapy in specific subtypes of sarcoma such as synovial sarcoma, which widely expresses the immunogenic cancer testis antigen NY-ESO-1.
Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice.
Blankenstein et al., Berlin, Germany. In Nat Biotechnol, Apr 2015
We also identify optimal-affinity TCRs specific for the CT antigen NY-ESO.
Treatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing.
Renner et al., Zürich, Switzerland. In Plos One, 2014
BACKGROUND: NY-ESO-1 belongs to the cancer/testis antigen (CTA) family and represents an attractive target for cancer immunotherapy.
Immunotherapy of Breast Cancer.
Curigliano et al., In Prog Tumor Res, 2014
These include vaccine approaches to elicit strong specific immune responses to tumor antigens such as WT-1, HER2 and NY-ESO-1, approaches involving adoptive transfer of in vitro-expanded, naturally arising or genetically engineered tumor-specific lymphocytes, therapeutic administration of monoclonal antibodies to target and eliminate tumor cells, and approaches that inhibit or destroy the molecular or cellular mediators of cancer-induced immunosuppression, such as CTLA-4, PD-1 or Treg cells.
Isolated Large Cell Calcifying Sertoli Cell Tumor in a Young Boy, not Associated with Peutz-Jeghers Syndrome or Carney Complex.
Stratakis et al., Bethesda, United States. In Ann Clin Lab Res, 2014
His tumor was studied by immunohistochemistry for the expression of calretinin, NY-ESO-1, inhibin, CD99, S100, PLAP, AE1/AE3, Bcl-2, p53, and Mib1.
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.
Chen et al., Princeton, United States. In J Clin Oncol, 2014
High pretreatment NY-ESO-1 and MART-1-specific CD8(+) T cells were associated with progression of disease.
NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis.
Lee et al., Bethesda, United States. In Mod Pathol, 2012
NY-ESO-1 is strongly and diffusely expressed in a majority of synovial sarcomas, but only rarely in other mesenchymal lesions. Suggest roles in targeted therapy and differential diagnosis.
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis.
Pawelec et al., Tübingen, Germany. In J Clin Oncol, 2012
The presence of circulating T cells responding to Melan-A or NY-ESO-1 had strong independent prognostic impact on survival in advanced melanoma.
Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma.
Sakaguchi et al., Ōsaka, Japan. In Blood, 2012
Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma.
Polymeric structure and host Toll-like receptor 4 dictate immunogenicity of NY-ESO-1 antigen in vivo.
Zeng et al., Los Angeles, United States. In J Biol Chem, 2011
Polymeric structure and TLR4 may play important roles in rendering NY-ESO-1 immunogenic and thus serve as a potent molecular adjuvant. NY-ESO-1 thus represents the first example of a cancer/testis antigen
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.
Gnjatic et al., New York City, United States. In Proc Natl Acad Sci U S A, 2011
Integrated NY-ESO-1 immune responses may have predictive value for ipilimumab treatment in patients with advanced metastatic melanoma.
share on facebooktweetadd +1mail to friends